IRCT20230303057599N1已完成3 期
The effectiveness of agomelatine on the severity and numbers of migraine attacks in patients with migraine
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •Migraine without aura without the use of preventive medicine
排除标准
- •Pregnant woman
- •those taking certain medications
研究者
相似试验
已完成
3 期
A clinical trial to study the effects of two drugs, Agomelatine and Venlafaxine ER in patients with major depressive disorder.CTRI/2011/04/001659Sun Pharmaceutical Industries Ltd200
已完成
3 期
Evaluation of the Efficacy of Agomelatine as Add-on Therapy on the Aggression, Agitation, and its Relationship with Serum Brain-Derived Neurotrophic Factor (BDNF) of Patients with Alzheimer’s disease DementiaBehavioral and Psychological Symptoms of Dementia.Alzheimer's diseaseIRCT20170608034390N10Shahid Beheshti University of Medical Sciences56
已完成
3 期
Efficacy of agomelatine given orally on improvement of subjective sleep in patients with major depressive disorder: a randomised, double-blind, flexible-dose international multicentre study with parallel groups versus Selective Serotonin Reuptake Inhibitor (SSRI) twelve week treatment plus double-blind extension for 12 weeksMental and Behavioural DisordersDepressive episodeMajor Depressive DisorderISRCTN55250367Institut de Recherches Internationales Servier (France)324
进行中（未招募）
1 期
Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus escitalopram (10 to 20mg/day). Twelve-week treatment plus double-blind extension for 12 weeks.MedDRA version: 9.1 Level: LLT Classification code 10057840 Term: Major depressionMajor Depressive DisorderEUCTR2006-006540-54-GBServier Research and Development Limited300
进行中（未招募）
不适用
Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus paroxetine (20 to 30 mg/day).Twelve-week treatment plus optional continuation for 12 weeks.MedDRA version: 3.3Level: P.T.Classification code 10025453Major Depressive DisorderEUCTR2005-002388-95-BEInstitut de Recherches Internationales Servier400